Genomic analysis of synchronous intracranial meningiomas with different histological grades

J Neurooncol. 2018 May;138(1):41-48. doi: 10.1007/s11060-018-2772-1. Epub 2018 Feb 8.

Abstract

Although meningioma is the most common primary tumor of the central nervous system, the mechanism of progression from benign to atypical or anaplastic grade remains elusive. The present case reports the genomic evaluation of two synchronous meningiomas with different histological grades (benign and atypical) in the same patient. Under the assumption that the atypical tumor may have progressed from the benign tumor, the clonal origin of the lesions was investigated to identify genomic events responsible for the oncogenic process of evolution to higher grades in meningioma. A 59 year-old female patient was diagnosed with two synchronous meningiomas with different histological grades, benign and atypical. Whole-exome sequencing (WES) and RNA sequencing (RNA-seq) analysis of both tumors were done. WES analysis showed that each meningioma harbored distinct mutation profiles, and RNA-seq analysis revealed distinct gene expression profiles between the two tumors. The only apparent common genetic abnormality found in both tumors was the loss of heterozygosity of chromosome 22, raising the possibility that this event is the initial step in tumor formation, after which distinct subsequent mutations lead to the evolvement of two separate tumors of different grades. The result provides additional evidence on previous reports suggesting separate, independent mechanism of progression into higher grades in meningioma.

Keywords: Atypical; Benign; Meningioma; RNA sequencing; Whole-exome sequencing.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Disease Progression
  • Female
  • Gene Expression
  • Genomics*
  • Humans
  • Meningeal Neoplasms / genetics*
  • Meningeal Neoplasms / pathology*
  • Meningioma / genetics*
  • Meningioma / pathology*
  • Middle Aged

Substances

  • Biomarkers, Tumor